Combination of IL-2 with cetuximab-coated or non-coated HNSCC cells (IL-2 with Cetmab or IL-2 alone) revealed no improvement of ADCC from X-VIVOTM10- and HP-treated NK cells, but inclusion of IL-2 significantly enhanced NK cell cytotoxicity compared to untreated NK cells (-IL-2) (Figure 4E, left/right graphs). The gene discussed is IL2; the disease is head and neck squamous cell carcinoma.